BTMD - NASDAQ
biote Corp.
$2.11
+5.5%biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
At a Glance
Live Snapshotbiote Corp. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
biote Corp. Cash Flow Statement
BTMD • NASDAQ
| biote Corp. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
27M | 46K | 3.3M | 1.3M | 32.6M | 29.2M | 21.3M | |
3.7M | 3.6M | 3M | 2.2M | 1.4M | 1.1M | 832K | |
4M | -2.9M | 721K | -743K | 0.0 | 0.0 | 0.0 | |
8.9M | 8.7M | 9.1M | 82.2M | 0.0 | 0.0 | 0.0 | |
-165K | 25.9M | 19.7M | -58.3M | 1.2M | 1.7M | 837K | |
(0.0) | (2.6M) | (4.4M) | (282K) | (171K) | (189K) | (178K) | |
-8.3M | 9.9M | -8.9M | -35.8M | -1.5M | -5.6M | 2.4M | |
35.2M | 45.2M | 26.9M | -9.2M | 33.7M | 26.4M | 25.4M | |
INVESTING ACTIVITIES | |||||||
-5M | -6.4M | -359K | -333K | -1.4M | -295K | -1.7M | |
(0.0) | -11.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.8M | -526K | -2.4M | -1.5M | -2.4M | -1.1M | -968K | |
-6.9M | -18.8M | -2.7M | -1.8M | -3.8M | -1.4M | -1.7M | |
FINANCING ACTIVITIES | |||||||
-3M | -5.3M | 144K | 18K | 0.0 | 0.0 | 0.0 | |
-1.3M | -6.3M | -6.3M | 84.4M | -5M | -5M | 44.2M | |
-1.7M | -4.7M | -8.7M | -12.9M | -11.4M | -13.3M | -56.6M | |
-3.4M | -5.6M | (0.0) | -424K | (0.0) | (0.0) | (0.0) | |
-37.6M | -59.8M | 420K | -8M | -3.9M | 0.0 | -1.1M | |
-43.6M | -76.1M | -14.4M | 63.5M | -20.3M | -18.3M | -13.6M | |
CASH FLOW SUMMARY | |||||||
6K | -22K | -19K | 0.0 | -12K | 9K | -9K | |
-15.2M | -49.7M | 9.8M | 52.5M | 9.6M | 6.7M | 10.1M | |
39.3M | 89M | 79.2M | 26.8M | 17.2M | 10.5M | 366K | |
24.1M | 39.3M | 89M | 79.2M | 26.8M | 17.2M | 10.5M | |
30.2M | 38.8M | 24.2M | -11M | 29.9M | 25M | 23.7M |
SEC Filings
BTMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | May 12, 2026 | 2026 |
Related Guides
Continue your BTMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.